- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02667353
Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression
Structural Brain Plasticity in Elderly Depressed Patients Following Electroconvulsive Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators want to study the potential neurorestorative effects of electroconvulsive therapy (ECT) in depressed patients by measuring brain derived neurotrophic factor (BDNF) serum levels and hippocampal volumes in severely depressed patients receiving ECT.
Clinical studies in severely depressed patients have shown that antidepressants and ECT can increase Brain Derived Neurotrophic Factor (BDNF) serum levels. BDNF serum levels will be measured before, during and after ECT. In animal studies this increase in serum BDNF was shown to induce hippocampal mossy fiber sprouting and the investigators want to study this phenomenon in humans. Recently, a volumetric magnetic resonance imaging study showed increased hippocampal volume in patients with depression. Hippocampal volumes will be determined with magnetic resonance imaging scannings including voxel based morphometry. Severe depression is accompanied by a dysfunction of the hypothalamus pituitary adrenal (HPA) axis. Cortisol and several other hormones have psychotropic effects, and their excesses or deficiencies induce states of mania or depression. High levels of cortisol suppress hippocampal neurogenesis. Animal models have shown that this suppressive effect of cortisol on hippocampal neurogenesis could be reversed to normal levels by electroconvulsive stimulation, the animal model for ECT. This animal study is in good accordance with clinical findings.
The investigators hypothesize the following: Increase of brain-derived neurotrophic factor serum levels induced by electroconvulsive therapy are associated with remission and is correlated with a neurorestorative effect, which is an increase of hippocampal volume. Non- response to ECT is explained by either low BDNF serum levels regardless of hippocampus size, or by (more advanced) medial temporal lobe atrophy (beyond a point of no return) despite increased BDNF serum levels.
Additionally, four relevant functional candidate genes will be examined, based on their putative role in neurotrophic processes and/or in treatment response in depression: the brain derived neurotrophic factor gene, the serotonin transporter gene, the vascular endothelial growth factor gene and the apolipoprotein gene.
The investigators will also evaluate cognitive and psychomotor changes following electroconvulsive therapy given their clinical relevance in late life depression.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients are considered suitable after they were diagnosed as having severe depression according to Diagnostic and Statistical Manual IV (DSM-IV criteria) and were above 55 years of age.
Exclusion Criteria:
- another major psychiatric illness, (a history of) a major neurological illness (including Parkinson's disease, stroke, and dementia) and metal implants precluding Magnetic Resonance Imaging (MRI).
Subjects were included at the University Psychiatric Center Katholieke Universiteit Leuven (KU Leuven), Belgium and Geestelijke Gezondheidszorg in Geest (GGZinGeest), Amsterdam, the Netherlands. The project is part of the project Mood Disorders in Elderly and Electroconvulsive therapy (MODECT).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: electroconvulsive therapy
only one arm in this study: patients who are treated with electroconvulsive therapy and have been given anesthesia with etomidate and succinylcholine
|
ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV).
Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality.
Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) < 10 in two consecutive ratings with a week interval).
Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
Other Names:
Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
Other Names:
Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in hippocampal volume as assessed by manual delineation following an initial automatic segmentation
Time Frame: 6 months
|
Hippocampal volumes were normalized using the following equation: normalised hippocampal volume = original hippocampal volume - linear regression coefficient x (total intracranial volume - mean total intracranial volume).
The coefficient was derived from a linear regression of total intracranial volume and original hippocampal volume.
Total intracranial volume was obtained from an automated segmentation of grey matter, white matter and cerebrospinal fluid.
Intra-rater reliability was determined using randomly selected scans segmented at two time-points at least one month apart.
The intra-class correlation coefficient (Cronbach's alfa) was 0.96 for the left hippocampus and 0.95 for the right hippocampus.
|
6 months
|
change in brain derived neurotrophic factor as assessed by the Emax Immuno Assay system
Time Frame: 4 weeks
|
Blood samples were taken between 07:30 am and 09:30 am after an overnight fast.
Serum was immediately separated and stored at -85 °celcius until assayed.
BDNF protein levels were measured using the Emax Immuno Assay system from Promega according to the manufacturer's protocol (Madison, United States of America), in one laboratory (Maastricht University).
Undiluted serum was acid treated as this reliably increased the detectable BDNF in a dilution-dependent way.
Greiner Bio-One high affinity 96-well plates were used.
Serum samples were diluted 100 times, and the absorbency was read in duplicate using a Bio-Rad (Hercules, United States of America) Benchmark microplate reader at 450 nm.
|
4 weeks
|
change of mood as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: up to 1 year
|
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.
Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6.
The overall score ranges from 0 to 60.
The questionnaire includes questions on the following symptoms: apparent sadness; reported sadness; inner tension; reduced sleep; reduced appetite; concentration difficulties; lassitude; inability to feel; pessimistic thoughts; suicidal thoughts.
|
up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change of cognition as assessed by the mini mental state examination
Time Frame: up to 1 year
|
The mini-mental state examination is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment.
The test includes questions in a number of areas: the time and place, repeating lists of words, arithmetic, and basic motor skills.
|
up to 1 year
|
change of psychomotor symptoms as assessed by the CORE (not an acronym)
Time Frame: up to 1 year
|
The CORE (this is not an acronym) was used to assess psychomotor symptoms in detail and comprises 18 observable features which are rated on a four-point scale.
Summing subsets of the items produces scores on three dimensions found to underlay psychomotor change: non-interactiveness, retardation and agitation.
|
up to 1 year
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Mathieu Vandenbulcke, MD PhD, Universitaire Ziekenhuizen KU Leuven
Publications and helpful links
General Publications
- Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003 Jan 24;112(2):257-69. doi: 10.1016/s0092-8674(03)00035-7.
- Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. doi: 10.1192/bjp.134.4.382.
- Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006 Jun 15;59(12):1116-27. doi: 10.1016/j.biopsych.2006.02.013. Epub 2006 Apr 21.
- UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003 Mar 8;361(9360):799-808. doi: 10.1016/S0140-6736(03)12705-5.
- Bolwig TG. How does electroconvulsive therapy work? Theories on its mechanism. Can J Psychiatry. 2011 Jan;56(1):13-8. doi: 10.1177/070674371105600104.
- Bocchio-Chiavetto L, Zanardini R, Bortolomasi M, Abate M, Segala M, Giacopuzzi M, Riva MA, Marchina E, Pasqualetti P, Perez J, Gennarelli M. Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. Eur Neuropsychopharmacol. 2006 Dec;16(8):620-4. doi: 10.1016/j.euroneuro.2006.04.010. Epub 2006 Jun 6.
- Bolwig TG, Madsen TM. Electroconvulsive therapy in melancholia: the role of hippocampal neurogenesis. Acta Psychiatr Scand Suppl. 2007;(433):130-5. doi: 10.1111/j.1600-0447.2007.00971.x.
- Chen AC, Shin KH, Duman RS, Sanacora G. ECS-Induced mossy fiber sprouting and BDNF expression are attenuated by ketamine pretreatment. J ECT. 2001 Mar;17(1):27-32. doi: 10.1097/00124509-200103000-00006.
- Fisman M, Rabheru K, Hegele RA, Sharma V, Fisman D, Doering M, Appell J. Apolipoprotein E polymorphism and response to electroconvulsive therapy. J ECT. 2001 Mar;17(1):11-4. doi: 10.1097/00124509-200103000-00003.
- Marano CM, Phatak P, Vemulapalli UR, Sasan A, Nalbandyan MR, Ramanujam S, Soekadar S, Demosthenous M, Regenold WT. Increased plasma concentration of brain-derived neurotrophic factor with electroconvulsive therapy: a pilot study in patients with major depression. J Clin Psychiatry. 2007 Apr;68(4):512-7. doi: 10.4088/jcp.v68n0404.
- Newton SS, Collier EF, Hunsberger J, Adams D, Terwilliger R, Selvanayagam E, Duman RS. Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci. 2003 Nov 26;23(34):10841-51. doi: 10.1523/JNEUROSCI.23-34-10841.2003.
- Nordanskog P, Dahlstrand U, Larsson MR, Larsson EM, Knutsson L, Johanson A. Increase in hippocampal volume after electroconvulsive therapy in patients with depression: a volumetric magnetic resonance imaging study. J ECT. 2010 Mar;26(1):62-7. doi: 10.1097/YCT.0b013e3181a95da8.
- Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJ, Beekman AT, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. J Clin Psychiatry. 2011 Jan;72(1):104-12. doi: 10.4088/JCP.08m04989blu. Epub 2010 Aug 24.
- Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12320-2. doi: 10.1073/pnas.231475998. No abstract available.
- Segi-Nishida E, Warner-Schmidt JL, Duman RS. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11352-7. doi: 10.1073/pnas.0710858105. Epub 2008 Aug 5.
- Steffens DC, Byrum CE, McQuoid DR, Greenberg DL, Payne ME, Blitchington TF, MacFall JR, Krishnan KR. Hippocampal volume in geriatric depression. Biol Psychiatry. 2000 Aug 15;48(4):301-9. doi: 10.1016/s0006-3223(00)00829-5.
- Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience. 1999 Mar;89(1):157-66. doi: 10.1016/s0306-4522(98)00289-9.
- Wagenmakers MJ, Oudega ML, Bouckaert F, Rhebergen D, Beekman ATF, Veltman DJ, Sienaert P, van Exel E, Dols A. Remission Rates Following Electroconvulsive Therapy and Relation to Index Episode Duration in Patients With Psychotic Versus Nonpsychotic Late-Life Depression. J Clin Psychiatry. 2022 Aug 10;83(5):21m14287. doi: 10.4088/JCP.21m14287.
- Carlier A, Rhebergen D, Veerhuis R, Schouws S, Oudega ML, Eikelenboom P, Bouckaert F, Sienaert P, Obbels J, Stek ML, van Exel E, Dols A. Inflammation and Cognitive Functioning in Depressed Older Adults Treated With Electroconvulsive Therapy: A Prospective Cohort Study. J Clin Psychiatry. 2021 Aug 10;82(5):20m13631. doi: 10.4088/JCP.20m13631.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Hypnotics and Sedatives
- Neuromuscular Agents
- Neuromuscular Blocking Agents
- Neuromuscular Depolarizing Agents
- Anesthetics
- Etomidate
- Succinylcholine
Other Study ID Numbers
- S53144
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Lawson Health Research InstituteTerminated
Clinical Trials on ECT
-
The University of New South WalesWesley MissionUnknown
-
The University of New South WalesSt George Hospital, Australia; Northside Clinic, Australia; The Melbourne Clinic... and other collaboratorsCompleted
-
Medical University of South CarolinaCompleted
-
Centre Hospitalier du RouvrayUniversity Hospital, Rouen; University Hospital, Caen; Centre Hospitalier Henri...CompletedMajor Depressive DisorderFrance
-
Pine Rest Christian Mental Health ServicesMclean HospitalCompletedAggression | Dementia | AgitationUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompletedDepressive Disorder, MajorGermany
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenRecruiting
-
Diakonhjemmet HospitalMD Tor Magne Bjølseth; MD Torfinn Lødøen GaardenCompleted
-
Kaohsiung Kai-Suan Psychiatric HospitalCompletedMajor Depressive EpisodeTaiwan